IRIDEX Corp
IRIX
View Detailed Chart
1.190USD
-0.090-7.03%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
20.01MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-7.03%
5 Days
-9.85%
1 Month
+3.03%
6 Months
+48.75%
Year to Date
-29.17%
1 Year
-38.66%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
IRIDEX Corporation is an ophthalmic medical technology company. It develops and commercializes products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probes products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
Growing
The company is in a growing phase, with the latest annual income totaling USD 48.67M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 18.06.
Undervalued
The company’s latest PE is -3.67, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 7.58M shares, increasing 4.37% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 585.81K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.39.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
IRIDEX Corporation is an ophthalmic medical technology company. It develops and commercializes products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probes products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
Ticker SymbolIRIX
CompanyIRIDEX Corp
CEOMr. Patrick Mercer
Websitehttps://www.iridex.com/
Related Instruments
-0.32%
+0.66%
-0.41%
-1.01%
-0.46%
-0.19%
-0.04%
-1.02%
+1.23%
-0.64%
-1.80%
-0.27%
-2.84%
-1.19%
-0.78%
-0.30%
+0.98%
-0.72%
-1.25%
-3.23%
